BRIEF-Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

Kymera Therapeutics, Inc. -0.96% Pre

Kymera Therapeutics, Inc.

KYMR

89.00

89.00

-0.96%

0.00% Pre

April 9 (Reuters) - Kymera Therapeutics Inc KYMR.O:

  • KYMERA THERAPEUTICS ANNOUNCES GILEAD SCIENCES’ OPTION EXERCISE TO LICENSE KT-200, ORAL CDK2 MOLECULAR GLUE DEGRADER DEVELOPMENT CANDIDATE

  • KYMERA THERAPEUTICS INC - TO RECEIVE $45 MILLION MILESTONE PAYMENT FROM GILEAD FOR KT-200 OPTION

  • KYMERA THERAPEUTICS INC - ELIGIBLE FOR UP TO $750 MILLION IN TOTAL PAYMENTS UNDER AGREEMENT

  • KYMERA THERAPEUTICS INC - HAS REALIZED $85 MILLION IN UPFRONT AND OPTION PAYMENTS TO DATE

  • KYMERA THERAPEUTICS INC - MAY RECEIVE TIERED ROYALTIES FROM HIGH SINGLE-DIGIT TO MID-TEENS ON SALES

  • KYMERA THERAPEUTICS INC - GILEAD TO ADVANCE KT-200 INTO IND-ENABLING STUDIES FOR 2027 IND FILING

Source text: ID:nGNX7PkM4m

Further company coverage: KYMR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.